Dimethyl Fumarate Can Enhance the Potential Therapeutic Effects of Epidermal Neural Crest Stem Cells in COVID-19 Patients

Safari, Anahid; Khodabandeh, Zahra; Borhani‐Haghighi, Afshin

doi:10.1007/s12015-020-10094-7

Cited by 5 publications

(5 citation statements)

References 10 publications

(13 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The topic of different DMT classes and their effect on COVID-19 course and hospitalization risk remains a controversial one. We found low dose interferons and dimethyl fumarate to have significantly lower relative risks in comparison with rituximab, findings that have been supported by other observations of high sample size in case of interferon by Sormani et al ( Sormani et al, 2021 ) and mechanistic predictions in case of dimethyl fumarate by Timpani et al ( Timpani and Rybalka, 2020 ) and Safari et al ( Safari et al, 2021 ). Although numerous studies and reviews have founds rituximab to have a worse effect on COVID-19 course compared to various DMTs ( Chaudhry et al, 2021 ) ( Sormani et al, 2021 ) ( LangerGould et al, 2021 ) ( Safavi et al, 2020 ), a recent review by Sharifian-Dorche et al does not support such an association ( SharifianDorche et al, 2021 ) which shows the need for further studies and more thorough investigation of accumulated data.…”

Section: Discussionsupporting

confidence: 89%

COVID-19 infection and hospitalization rate in Iranian multiple sclerosis patients: What we know by May 2021

Naghavi

Kavosh

Adibi

et al. 2022

Multiple Sclerosis and Related Disorders

View full text Add to dashboard Cite

Background : Despite investigations on the effect of disease modifying therapies (DMTs) used in multiple sclerosis (MS) on coronavirus disease 2019 (COVID-19); there are still controversies. Objective : We designed this study to evaluate the epidemiological features of covid-19 in a large sample of people with MS (pwMS) in Isfahan, Iran, as well as the association between DMTs, risk of COVID-19 infection and hospitalization. Methods : In an observational pwMS, we interviewed subjects on their MS and COVID-19 history. Results : 3050 subjects were included (74% female) with a mean age of 41.36. 423 (13.8%) had confirmed COVID-19 which shows that pwMS are at a higher risk of infection compared to the general population, No significant relationship was observed in COVID-19 infection when individual drugs. Dimethyl fumarate and rituximab had the lowest and the highest relative risks for hospitalization rate compared to other drugs, respectively. Conclusion : We found no evidence supporting a higher prevalence of COVID-19 in pwMS compared to the general population. However, our results show pwMS to be more prone to hospitalization compared to the general population, Therefore, it is advised to use safer treatment if possible until complete vaccination, and to postpone the use of rituximab.

show abstract

Section: Discussionsupporting

confidence: 89%

COVID-19 infection and hospitalization rate in Iranian multiple sclerosis patients: What we know by May 2021

Naghavi

Kavosh

Adibi

et al. 2022

Multiple Sclerosis and Related Disorders

View full text Add to dashboard Cite

show abstract

“…Currently, the most widely used Nrf2 activator is the fumaric acid ester dimethyl fumarate (DMF) (Robledinos-Anton et al 2019 ; Safari et al 2021 ). DMF is a potent antioxidant and anti-inflammatory drug that modulates inflammation and oxidative stress, and hence cytoprotection, by upregulating cellular defense mechanisms, such as the expression of phase II antioxidants.…”

Section: Nrf2 Activators For Potential Therapy Of Covid-19mentioning

confidence: 99%

Transcription factor Nrf2 as a potential therapeutic target for COVID-19

Wang

Jiang

2023

Cell Stress and Chaperones

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID-19) is caused by a novel severe acute respiratory syndrome (SARS)–like coronavirus (SARS-CoV-2). Critically ill patients with SARS-COV-2 infection frequently exhibit signs of high oxidative stress and systemic inflammation, which accounts for most of the mortality. Antiviral strategies to inhibit the pathogenic consequences of COVID-19 are urgently required. The nuclear factor erythroid 2–related transcription factor (Nrf2) is a transcription factor that is involved in antioxidant and anti-inflammatory defense in several tissues and cells. This review tries to present an overview of the role of Nrf2 in the treatment of COVID-19.

show abstract

“…92 Another activator of Nrf2, fumaric acid ester DMF, can also inhibit NF-kB signalling, which is activated through the ACE2 locus. 93,94 Hence, DMF can be one of the that resulted in the inhibition of viral translation by making the SARS-CoV2 5 0 UTR susceptible to NSP1 suppression. 54 Similarly, NSP1 can also be targeted as it is one of the key proteins required for host translation inhibition, as shown in Figure 3A, and it is also known to regulate the immune response.…”

Section: Molecular Machineries As a Therapeutic Targetmentioning

confidence: 99%

“…PB125, an Nrf2 activator, is known to decrease expression of both ACE2 and TMPRSS2, thus inhibiting viral entry 92 . Another activator of Nrf2, fumaric acid ester DMF, can also inhibit NF‐kB signalling, which is activated through the ACE2 locus 93,94 . Hence, DMF can be one of the potent drugs to inhibit viral infection by promoting antioxidant activity and inhibiting the release of pro‐inflammatory cytokines.…”

Section: Molecular Machineries As a Therapeutic Targetmentioning

confidence: 99%

Modulation of various host cellular machinery during COVID‐19 infection

Malvankar,

Singh,

Ravi Kumar

et al. 2023

Reviews in Medical Virology

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV2) emerged in December 2019, causing a range of respiratory infections from mild to severe. This resulted in the ongoing global COVID‐19 pandemic, which has had a significant impact on public health. The World Health Organization declared COVID‐19 as a global pandemic in March 2020. Viruses are intracellular pathogens that rely on the host's machinery to establish a successful infection. They exploit the gene expression machinery of host cells to facilitate their own replication. Gaining a better understanding of gene expression modulation in SARS‐CoV2 is crucial for designing and developing effective antiviral strategies. Efforts are currently underway to understand the molecular‐level interaction between the host and the pathogen. In this review, we describe how SARS‐CoV2 infection modulates gene expression by interfering with cellular processes, including transcription, post‐transcription, translation, post‐translation, epigenetic modifications as well as processing and degradation pathways. Additionally, we emphasise the therapeutic implications of these findings in the development of new therapies to treat SARS‐CoV2 infection.

show abstract

Dimethyl Fumarate Can Enhance the Potential Therapeutic Effects of Epidermal Neural Crest Stem Cells in COVID-19 Patients

Cited by 5 publications

References 10 publications

COVID-19 infection and hospitalization rate in Iranian multiple sclerosis patients: What we know by May 2021

COVID-19 infection and hospitalization rate in Iranian multiple sclerosis patients: What we know by May 2021

Transcription factor Nrf2 as a potential therapeutic target for COVID-19

Modulation of various host cellular machinery during COVID‐19 infection

Contact Info

Product

Resources

About